Search
Arcturus Therapeutics Holdings Inc
ARCTAdd to Watchlist
14.120USD
+0.820+6.17%
Close 09-24 16:00（ET）
401.29MMarket Cap
LossP/E TTM
Arcturus Therapeutics Holdings Inc (ARCT) Stock Price Target & Forecast
Analyst Rating
Based on 12 analysts giving stock ratings to Arcturus Therapeutics Holdings Inc in the past month.
Buy
3 Strong Buy
6 Buy
3 Hold
0 Sell
0 Strong Sell
Target Price
22.000USD+65.41%
ARCT Analyst Recommendation Trends
In the current month, ARCT has received 6 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. ARCT average Analyst price target in the last month is 22.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
3
3
3
3
3
6
6
7
7
6
6
5
5
3
3
3
3
3
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
12
13
13
12
12
11
11
ARCT Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, ARCT EPS is projected to reach -0.679 in FY2026Q3, following reported EPS of -0.837 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.71
-1.09
-1.00
-0.68
-0.89
Actual
-1.03
-0.95
-0.84
--
--
Surprise
-45.03%
+12.85%
+16.20%
--
--
FAQs
What is Arcturus Therapeutics Holdings Inc's expected revenue for the next quarter?
Arcturus Therapeutics Holdings Inc's expected revenue is 8.00M.
What is Arcturus Therapeutics Holdings Inc's price target?
Analysts forecast that Arcturus Therapeutics Holdings Inc's price target is USD 22.30, with the highest forecast at USD 41.00 and the lowest forecast at USD 8.00.
How have Arcturus Therapeutics Holdings IncARCT's recent earnings per share performed?
The market expectation was USD -0.84, while Arcturus Therapeutics Holdings IncARCT's earnings per share (EPS) for the previous quarter was USD -0.95. EPS for the next quarter is expected at USD -0.68.
What is the analyst rating for Arcturus Therapeutics Holdings Inc?
Based on the ratings of Arcturus Therapeutics Holdings Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.